Titan Pharmaceuticals (NASDAQ:TTNP) reported that Crossroads of Southern Nevada rehabilitation facility has trained health care providers in the insertion and removal of Probuphine implants, which will now be offered to...
Bettina Cockroft Sangamo Therapeutics (NASDAQ:SGMO) appointed Dr. Bettina Cockroft as SVP and CMO to oversee clinical development activities and operations. Sangamo is using its ex vivo gene-edited cell...
Geron’s (NASDAQ:GERN) imetelstat, a telomerase inhibitor, received FDA fast track designation for the treatment of relapsed/refractory myelofibrosis (MF). MF is a chronic blood cancer that impairs normal blood...
Stifel launched coverage of Fate Therapeutics (NASDAQ:FATE) with a “buy” rating and $27 price target. The stock closed at $15.47 on Sept. 28. Fate is using its induced pluripotent stem cell (iPSC) platform to develop...
Alliance Global Partners raised its price target for OpGen (NASDAQ:OPGN) to $11 from a reverse-split adjusted $8 after an analysis of its proposed merger with Curetis (Euronext:CURE), an infectious disease molecular...
Roth Capital Partners launched coverage of Daxor (NYSE American:DXR) with a “neutral” rating and $18 price target. The stock closed at $9.62 on Sept. 27. Daxor is an investment management company, with a medical device...
Daniel Goldberger electroCore (NASDAQ:ECOR) has appointed Daniel Goldberger as CEO, effective Oct. 1. Mr. Goldberger has more than 35 years of experience in the biotechnology and medical technology industries; with...
AVEO Oncology (NASDAQ:AVEO) began enrolling patients for its Phase 1b/2 clinical trial evaluating FOTIVDA, in combination with AstraZeneca’s IMFINZI, in patients with hepatocellular carcinoma (HCC) who have not received...
The FDA cleared Turning Point Therapeutics’ (NASDAQ:TPTX) IND for TPX-0046, a dual RET and SRC tyrosine kinase inhibitor (TKI) being developed for the treatment of solid tumors. The company plans to initiate a first-in...
Zenabis Global (TSX:ZENA) has agreed to supply cannabis extracts for PAX Era pods, which are designed for use with PAX Labs’ Era vaporizer device. Under the accord, Zenabis will supply cannabis extracts in the form...
Stifel downgraded Concert Pharmaceuticals (NASDAQ:CNCE) to “hold” from “buy” and lowered its price target to $8 from $18 after the company reported a Phase 3 trial failure with its AVP-786 drug candidate in Alzheimer’s...
Cheryl Reicin, partner at Torys, was named Canada’s financial and corporate attorney of the year at the seventh annual LMG Life Sciences awards. Ms. Reicin is the practice leader of Torys’ life science group...